Zobrazeno 1 - 10
of 248
pro vyhledávání: '"Heemskerk, M.H.M."'
Autor:
Arbous, M.S., van den Berg, B.M., Cannegieter, S., Cobbaert, C.M., van der Does, A., van Dongen, J.J.M., Eikenboom, J., Feltkamp, M.C.M., Geluk, A., Goeman, J.J., Giera, M., Hankemeier, T., Heemskerk, M.H.M., Hiemstra, P.S., Hokke, C.H., Janse, J.J., Jochems, S.P., Joosten, S.A., Kikkert, M., Lamont, L., Manniën, J., Ottenhoff, T.H.M., del Prado, M.R., Queralt Rosinach, N., Roestenberg, M., Roos, M., Roukens, A.H.E., Smits, H.H., Snijder, E.J., Staal, F.J.T., Trouw, L.A., Tsonaka, R., Verhoeven, A., Visser, L.G., de Vries, J.J.C., van Westerloo, D.J., Wigbers, J., van der Wijk, H.J., van Wissen, R.C., Wuhrer, M., Yazdanbakhsh, M., Zlei, M., Pierneef, Louise, van Hooij, Anouk, de Jong, Danielle, Tjon Kon Fat, Elisa M., van Meijgaarden, Krista E., Petruccioli, Elisa, Vanini, Valentina, Roukens, Anna H.E., Goletti, Delia, Corstjens, Paul L.A.M., Joosten, Simone A., Geluk, Annemieke
Publikováno v:
In iScience 20 January 2023 26(1)
Autor:
Heemskerk, M.H.M.
Oratie uitgesproken door Prof. dr. Mirjam H.M. Heemskerk bij de aanvaarding van het ambt van hoogleraar met als leeropdracht Immunotherapie van Kanker, in het bijzonder het ontwikkelen van celtherapie aan de Universiteit Leiden op vrijdag 2 juni 2023
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______202::58aab393ba8915601e2fc5fa9bed69f4
https://hdl.handle.net/1887/3618867
https://hdl.handle.net/1887/3618867
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Meeuwsen, M.H., Wouters, A.K., Wachsmann, T.L.A., Hagedoorn, R.S., Kester, M.G.D., Remst, D.F.G., Steen, D.M. van der, Ru, A.H. de, Hees, E.P. van, Kremer, M., Griffioen, M., Veelen, P.A. van, Falkenburg, J.H.F., Heemskerk, M.H.M.
Publikováno v:
Journal of Hematology and Oncology, 16(1). BMC
Background The immunoglobulin J chain (Jchain) is highly expressed in the majority of multiple myeloma (MM), and Jchain-derived peptides presented in HLA molecules may be suitable antigens for T-cell therapy of MM. Methods Using immunopeptidomics, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c1e2f6ddb1f105d12c9b23397f7c32f
https://doi.org/10.1186/s13045-023-01408-6
https://doi.org/10.1186/s13045-023-01408-6
Autor:
Roukens, A.H.E., Pothast, C.R., Konig, M., Huisman, W., Dalebout, T., Tak, T., Azimi, S., Kruize, Y., Hagedoorn, R.S., Zlei, M., Staal, F.J.T., Bie, F.J. de, Dongen, J.J.M. van, Arbous, S.M., Zhang, J.L.H., Verheij, M., Prins, C., Does, A.M. van der, Hiemstra, P.S., Vries, J.J.C. de, Janse, J.J., Roestenberg, M., Myeni, S.K., Kikkert, M., Yazdanbakhsh, M., Heemskerk, M.H.M., Smits, H.H., Jochems, S.P., Collaboration BEAT-COVID Grp, Collaboration COVID-19 LUMC Grp
Publikováno v:
Nature Immunology, 23, 23-32. NATURE PORTFOLIO
Systemic immune cell dynamics during coronavirus disease 2019 (COVID-19) are extensively documented, but these are less well studied in the (upper) respiratory tract, where severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicates(1-6).
Publikováno v:
None
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab085e31b326f8fdaf31a1f67d45303c
https://doi.org/10.1002/ajh.26780
https://doi.org/10.1002/ajh.26780
Autor:
Haggenburg, S., Hofsink, Q., Lissenberg-Witte, B.I., Broers, A.E.C., Doesum, J.A. van, Binnendijk, R.S. van, Hartog, G. den, Bhoekhan, M.S., Haverkate, N.J.E., Burger, J.A., Bouhuijs, J.H., Smits, G.P., Wouters, D., Leeuwen, E.M.M. van, Bontkes, H.J., Kootstra, N.A., Zweegman, S., Kater, A.P., Heemskerk, M.H.M., Groen, K., Meerten, T. van, Mutsaers, P.G.N.J., Beaumont, T., Gils, M.J. van, Goorhuis, A., Rutten, C.E., Hazenberg, M.D., Nijhof, I.S., Cobra Kai Study Team
Publikováno v:
Haggenburg, S, Hofsink, Q, Lissenberg-Witte, B I, Broers, A E C, van Doesum, J A, van Binnendijk, R S, den Hartog, G, Bhoekhan, M S, Haverkate, N J E, Burger, J A, Bouhuijs, J H, Smits, G P, Wouters, D, van Leeuwen, E M M, Bontkes, H J, Kootstra, N A, Zweegman, S, Kater, A P, Heemskerk, M H M, Groen, K, van Meerten, T, Mutsaers, P G N J, Beaumont, T, van Gils, M J, Goorhuis, A, Rutten, C E, Hazenberg, M D & Nijhof, I S 2022, ' Antibody Response in Immunocompromised Patients with Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19 ', JAMA Oncology, vol. 8, no. 10, pp. 1477-1483 . https://doi.org/10.1001/jamaoncol.2022.3227
JAMA Oncology, 8(10), 1477-1483. American Medical Association
JAMA oncology, 8(10), 1477-1483. AMER MEDICAL ASSOC
JAMA Oncology, 8(10), 1477-1483. AMER MEDICAL ASSOC
JAMA oncology, 8(10), 1477-1483. American Medical Association
JAMA Oncology, 8(10), 1477-1483. American Medical Association
JAMA oncology, 8(10), 1477-1483. AMER MEDICAL ASSOC
JAMA Oncology, 8(10), 1477-1483. AMER MEDICAL ASSOC
JAMA oncology, 8(10), 1477-1483. American Medical Association
ImportanceIt has become common practice to offer immunocompromised patients with hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce.ObjectiveTo assess whether a third mRNA-1273 vaccination is associated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4540836a714070839e1bdeed6825e303
https://research.vumc.nl/en/publications/7c4334ec-660d-4280-8ec8-447119d024c7
https://research.vumc.nl/en/publications/7c4334ec-660d-4280-8ec8-447119d024c7
Autor:
Zlei, M., Sidorov, I.A., Joosten, S.A., Heemskerk, M.H.M., Myeni, S.K., Pothast, C.R., Brouwer, C.S. de, Boomaars-van der Zanden, A.L., Meijgaarden, K.E. van, Morales, S.T., Wessels, E., Janse, J.J., Goeman, J.J., Cobbaert, C.M., Kroes, A.C.M., Cannegieter, S.C., Roestenberg, M., Visser, L.G., Kikkert, M., Feltkamp, M.C.W., Arbous, S.M., Staal, F.J.T., Ottenhoff, T.H.M., Dongen, J.J.M. van, Roukens, A.H.E., Vries, J.J.C. de, Collaboration BEAT-COVID, Collaboration LUMC COVID
Publikováno v:
Cells, 11(17). MDPI
Cells; Volume 11; Issue 17; Pages: 2743
Cells; Volume 11; Issue 17; Pages: 2743
Virus-specific cellular and humoral responses are major determinants for protection from critical illness after SARS-CoV-2 infection. However, the magnitude of the contribution of each of the components to viral clearance remains unclear. Here, we st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d59ed86266a323bdc5138c07c573c79
https://hdl.handle.net/1887/3479829
https://hdl.handle.net/1887/3479829
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.